Investigational drug · Phase 2
CC-38
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CC-38"
First trial start
2025
Nov 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CC-38", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
- Prostate Cancer Metastatic
- Prostate Cancer Locally Advanced
Approved drugs for the same conditions: Prostate cancer · Colorectal cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CC-38" as an intervention, largest first.
CuraCell TX ABIndustry
NCT07255664 · 12 participants (planned) · Start Nov 13, 2025 · Primary completion Apr 2027
Drug: CC-38; Pembrolizumab and 3 more · For: Metastatic Colorectal Cancer; Prostate Cancer Metastatic; Prostate Cancer Locally Advanced
Sites: Frankfurt, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Immuno-spin trapping after intraarticular procedures shows coordination between radical production, iron metabolism, and mitochondria in articular chondrocytes.
Hines MR, Witt E, McNally LD, et al. · Osteoarthritis Cartilage 2026
- Treatment modality in older patients with end-stage kidney disease: Description and retrospective follow-up of a center's cohort.
Mendes B, Farinha A, Fonseca F, et al. · Rev Esp Geriatr Gerontol 2026
- Effect of green mediterranean diet on serum folate and its interaction with genetic variation in folate metabolism: The DIRECT PLUS 18-month dietary randomized controlled trial.
Zelicha H, Keller M, Meir AY, et al. · Clin Nutr 2026
- The readiness of primary healthcare facilities to address non-communicable diseases in rural Bangladesh.
Sarker T, Xie W, Ahsan A, et al. · BMC Health Serv Res 2026
- Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.
Rothnie K, Tristano E, Diaz-Rodriguez M, et al. · Gynecol Oncol 2026
- Comparative Diagnostic Utility of Cell Cytology, Cell Block, Pleural Brushing, and Pleural Biopsy in Exudative Pleural Effusions.
Shah PAA, Bashir M, Farooq M, et al. · Cureus 2025
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.